Report of Foreign Issuer (6-k)
May 08 2019 - 2:03PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of May, 2019
Commission
File Number 001-15170
GlaxoSmithKline plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8
9GS
(Address
of principal executive office)
Indicate by check
mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
GlaxoSmithKline plc
Result of Annual General Meeting and General Meeting
GlaxoSmithKline plc ('GSK') announces that at its
Annual General Meeting ('AGM') and General Meeting today, all
resolutions were passed by shareholders. The full text of the
resolutions considered are contained in the 2019 Notice of AGM and
the sole resolution of the General Meeting is contained in the
Circular to Shareholders and Notice of General Meeting. These
documents are available on the GSK website
at
www.gsk.com
.
GSK AGM Poll Results
The
following table shows the total number of votes cast for each
resolution:
Resolution
|
Total
votes for
*
|
%
|
Total
votes against
|
%
|
Total votes cast
|
Votes withheld
**
|
1
|
Receive
and adopt the 2018 Annual Report
|
3,556,826,649
|
99.95
|
1,863,433
|
0.05
|
3,558,690,082
|
7,283,024
|
2
|
Approve
the Annual report on remuneration
|
3,157,857,593
|
88.77
|
399,443,579
|
11.23
|
3,557,301,172
|
8,672,905
|
3
|
Election
of Iain Mackay
|
3,509,580,387
|
98.56
|
51,394,236
|
1.44
|
3,560,974,623
|
4,999,291
|
4
|
Re-election
of Philip Hampton
|
3,523,220,874
|
98.94
|
37,814,132
|
1.06
|
3,561,035,006
|
4,939,054
|
5
|
Re-election
of Emma Walmsley
|
3,543,610,930
|
99.50
|
17,645,007
|
0.50
|
3,561,255,937
|
4,724,016
|
6
|
Re-election
of Vindi Banga
|
3,520,241,639
|
98.87
|
40,257,748
|
1.13
|
3,560,499,387
|
5,474,256
|
7
|
Re-election
of Dr Hal Barron
|
3,542,101,484
|
99.46
|
19,107,976
|
0.54
|
3,561,209,460
|
4,763,464
|
8
|
Re-election
of Dr Vivienne Cox
|
3,494,225,537
|
98.85
|
40,751,267
|
1.15
|
3,534,976,804
|
30,997,813
|
9
|
Re-election
of Lynn Elsenhans
|
3,543,230,972
|
99.50
|
17,848,986
|
0.50
|
3,561,079,958
|
4,893,685
|
10
|
Election
of Dr Laurie Glimcher
|
3,543,924,853
|
99.52
|
17,255,115
|
0.48
|
3,561,179,968
|
4,793,241
|
11
|
Re-election
of Dr Jesse Goodman
|
3,543,465,739
|
99.50
|
17,643,172
|
0.50
|
3,561,108,911
|
4,864,732
|
12
|
Re-election
of Judy Lewent
|
3,513,131,684
|
98.66
|
47,693,254
|
1.34
|
3,560,824,938
|
5,154,954
|
13
|
Re-election
of Urs Rohner
|
3,434,585,693
|
96.46
|
126,031,133
|
3.54
|
3,560,616,826
|
5,356,667
|
14
|
Re-appointment
the auditor
|
3,557,236,743
|
99.88
|
4,327,420
|
0.12
|
3,561,564,163
|
4,412,192
|
15
|
Remuneration
of auditor
|
3,554,992,184
|
99.83
|
6,020,952
|
0.17
|
3,561,013,136
|
4,948,179
|
16
|
Authority
for the company to make donations to political organisations and
incur political expenditure
|
3,471,514,277
|
98.00
|
70,681,915
|
2.00
|
3,542,196,192
|
23,791,786
|
17
|
Authority
to allot shares
|
3,444,525,603
|
96.77
|
114,953,481
|
3.23
|
3,559,479,084
|
6,482,169
|
18
|
Disapplication
of pre-emption rights - general power
***
|
3,480,629,187
|
97.84
|
76,741,126
|
2.16
|
3,557,370,313
|
8,607,071
|
19
|
Disapplication
of pre-emption rights - in connection with an acquisition or
specified capital investment
***
|
3,390,801,857
|
95.31
|
166,798,143
|
4.69
|
3,557,600,000
|
8,370,163
|
20
|
Authority
for the company to purchase its own shares
***
|
3,509,141,893
|
98.57
|
50,794,321
|
1.43
|
3,559,936,214
|
6,028,543
|
21
|
Exemption
from statement of senior statutory auditor's name
|
3,524,087,916
|
99.51
|
17,395,554
|
0.49
|
3,541,483,470
|
24,488,266
|
22
|
Authority
for reduced notice of a general meeting other than an
AGM
***
|
3,271,677,728
|
92.38
|
269,908,346
|
7.62
|
3,541,586,074
|
24,387,840
|
GSK General Meeting Poll Results
The following table shows the total number of votes cast for the
resolution:
Resolution
|
Total
votes for
*
|
%
|
Total
votes against
|
%
|
Total votes cast
|
Votes withheld
**
|
1
|
To
approve the transaction between GlaxoSmithKline plc,
GlaxoSmithKline Consumer Healthcare Holdings Limited and Pfizer,
Inc for the purposes of Chapter 11 of the Listing Rules of the
Financial Conduct Authority
|
3,496,633,023
|
99.85
|
5,302,329
|
0.15
|
3,501,935,352
|
24,272,073
|
|
|
|
|
|
|
|
|
Notes:
*
|
Includes
discretionary votes. In line with the notification issued to
American Depositary Receipt (ADR) holders earlier this year, GSK
did not instruct its ADR Depositary to vote any unvoted ADRs in
respect of the resolutions for the 2019 AGM and GM
|
**
|
A vote
withheld is not a vote in law and is not counted in the calculation
of the proportion of votes "For" or "Against" a
resolution.
|
***
|
Indicates
Special Resolutions requiring a 75% majority.
|
The above poll results will shortly be available
on the Company's website at
www.gsk.com
.
In accordance with Listing Rule 9.6.2, a copy of the resolutions,
other than those concerning ordinary business, will be submitted to
the UK Listing Authority and will in due course be available for
inspection at
www.morningstar.co.uk/uk/NSM
Simon
Dingemans did not stand for re-election as a Director and retired
from the Board with effect from the conclusion of the
AGM.
In
accordance with section 430(2B) of the Companies Act 2006, GSK
confirms that Simon Dingemans will receive payment of fees for
service whilst a Director, but no other remuneration payment or
payment for loss of office will be made in connection with his
departure.
The
following table provides further relevant information:
|
GSK's
Nineteenth
AGM
(2019)
|
GSK's
Eighteenth
AGM
(2018)
|
Issued
share capital (excluding Treasury Shares)
|
4,987,806,108
|
4,959,302,644
|
Total
votes cast and votes withheld lodged as a % of GSK's issued share
capital (excluding Treasury Shares)
|
71.49%
|
78.76%
|
Total
shareholder population
|
108,698
|
112,326
|
Total
number of proxies lodged
|
6,635
|
6,931
|
% of
shareholders who lodged proxies
|
6.10%
|
6.17%
|
Number
of shareholders, corporate representatives and proxies who attended
the AGM
|
241
|
415
|
V A Whyte
Company Secretary
8 May 2019
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
GlaxoSmithKline plc
|
|
(Registrant)
|
|
|
Date: May
08, 2019
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GlaxoSmithKline plc
|
GSK (NYSE:GSK)
Historical Stock Chart
From Aug 2024 to Sep 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Sep 2023 to Sep 2024